Published in Proteomics Weekly, March 7th, 2005
According to a study from the United States, "It is now widely accepted that various LMWHs exhibit specific molecular and structural attributes that are determined by the type of manufacturing process used. For example, enoxaparin, which is prepared by benzylation followed by alkaline hydrolysis of unfractionated heparin, exhibits a double bond at the nonreducing end and the presence of a unique bicyclic structure namely 1,6-anhydro-mannoglucose or mannose, or both, at the reducing end. Similarly, the other LMWHs, such as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly